- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | ZHAOKE OPHTH-B (06622): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | - | HKEx | ||
| ZHAOKE OPHTHALMOLOGY Aktie jetzt für 0€ handeln | |||||
| 14.08. | ZHAOKE OPHTH-B (06622): NOTICE OF BOARD MEETING | - | HKEx | ||
| 04.08. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - MEDICAL DEVICE REGISTRATION CERTIFICATE OBTAINED FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR ... | 1 | HKEx | ||
| 30.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ORPHAN DRUG DESIGNATION RECEIVED FROM THE U.S FDA FOR MELPHALAN TARGETING PEDIATRIC RETINOBLASTOMA | 4 | HKEx | ||
| 15.07. | Zhaoke Ophthalmology, Fareva Sign Memorandum of Agreement | 1 | Contract Pharma | ||
| 09.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF NEW DRUG APPLICATION FOR NVK002 (ATROPINE SULPHATE EYE DROPS 0.02%) FOR THE TREATMENT ... | 1 | HKEx | ||
| 02.07. | ZHAOKE OPHTH-B (06622): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 02.07. | ZHAOKE OPHTH-B (06622): CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 30.06. | ZHAOKE OPHTH-B (06622): NOMINATION COMMITTEE - TERMS OF REFERENCE | 1 | HKEx | ||
| 12.06. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR TAB014 FOR THE TREATMENT OF WAMD | 1 | HKEx | ||
| 04.06. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - FDA CLEARANCE OF IND APPLICATION FOR CSA OPHTHALMIC GEL | 3 | HKEx | ||
| 19.05. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF NEW DRUG APPLICATION FOR CSA OPHTHALMIC GEL | - | HKEx | ||
| 16.05. | ZHAOKE OPHTH-B (06622): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 16, 2025 | - | HKEx | ||
| 24.04. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 24.04. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 24.04. | ZHAOKE OPHTH-B (06622): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 16, 2025 | - | HKEx | ||
| 24.04. | ZHAOKE OPHTH-B (06622): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.04. | ZHAOKE OPHTH-B (06622): (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING ... | 1 | HKEx | ||
| 24.04. | ZHAOKE OPHTH-B (06622): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 | - | HKEx | ||
| 24.04. | ZHAOKE OPHTH-B (06622): 2024 ANNUAL REPORT | - | HKEx |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,215 | +0,11 % | dpa-AFX-Überblick: UNTERNEHMEN vom 29.08.2025 - 15.15 Uhr | ROUNDUP: Gerresheimer bekommt überraschend neuen Finanzchef - Aktie erholt DÜSSELDORF - Der zuletzt schwächelnde Pharmaverpackungshersteller Gerresheimer bekommt überraschend einen neuen Finanzchef.... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,905 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| EVOTEC | 5,702 | -2,70 % | Evotec Aktie: Bringt der "Insiderkauf" die große Kurs-Wende? | Ein großer "Insiderkauf" machte bei der Evotec Aktie in dieser Woche Schlagzeilen. Wer dachte, dass der Aktienkauf des CEO von Evotec im Wert von knapp 0,3 Millionen Euro aber massive Dynamik in die... ► Artikel lesen | |
| VERA THERAPEUTICS | 21,900 | -4,62 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 35,510 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 19,760 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 33,175 | 0,00 % | Mineralys Therapeutics closes $287.5 million public offering | ||
| TAYSHA GENE THERAPIES | 3,260 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 37,130 | -2,75 % | Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum | ||
| PRAXIS PRECISION MEDICINES | 46,090 | -1,01 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOME | 9,800 | -4,39 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| PHATHOM PHARMACEUTICALS | 12,000 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| BIONTECH | 89,10 | +3,42 % | BioNtech Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| EDGEWISE THERAPEUTICS | 14,620 | -0,10 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,805 | 0,00 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress |
Das Unternehmen ZHAOKE OPHTHALMOLOGY LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,408 Euro und damit +0,99 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZHAOKE OPHTHALMOLOGY LTD finden Sie auf Wallstreet Online.